In the present study, we assessed the effect of per os (p.o.)dosing of a new orally bioavailable Nav1.8-selective blocker, PF-01247324, in transgenic mice expressing Nav1.8 in Purkinje neurons, and in wildtype mice in the experimental autoimmune encephalomyelitis (EAE) model. The gene discussed is SCN10A; the disease is experimental autoimmune encephalomyelitis.